0001493152-21-014435.txt : 20210615
0001493152-21-014435.hdr.sgml : 20210615
20210615171433
ACCESSION NUMBER: 0001493152-21-014435
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20210615
DATE AS OF CHANGE: 20210615
EFFECTIVENESS DATE: 20210615
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: BriaCell Therapeutics Corp.
CENTRAL INDEX KEY: 0001610820
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: A1
FISCAL YEAR END: 0731
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-403035
FILM NUMBER: 211019556
BUSINESS ADDRESS:
STREET 1: 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR
CITY: WEST VANCOUVER
STATE: A1
ZIP: V7T 2X1
BUSINESS PHONE: (604) 921-1810
MAIL ADDRESS:
STREET 1: 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR
CITY: WEST VANCOUVER
STATE: A1
ZIP: V7T 2X1
FORMER COMPANY:
FORMER CONFORMED NAME: Ansell Capital Corp.
DATE OF NAME CHANGE: 20140613
D
1
primary_doc.xml
X0708
D
LIVE
0001610820
BriaCell Therapeutics Corp.
SUITE 300-235 15TH STREET
WEST VANCOUVER
A1
BRITISH COLUMBIA, CANADA
V7T2X1
(604) 921-1810
BRITISH COLUMBIA, CANADA
None
Ansell Capital Corp.
Corporation
true
William
Williams
Suite 300-235 15th Street
West Vancouver
A1
BRITISH COLUMBIA, CANADA
V7T2X1
Executive Officer
Director
Gadi
Levin
Suite 300-235 15th Street
West Vancouver
A1
BRITISH COLUMBIA, CANADA
V7T2X1
Executive Officer
Rebecca
Taub
Suite 300-235 15th Street
West Vancouver
A1
BRITISH COLUMBIA, CANADA
V7T2X1
Director
Vaughn
Embro-Pantalony
Suite 300-235 15th Street
West Vancouver
A1
BRITISH COLUMBIA, CANADA
V7T2X1
Director
Jamieson
Bondarenko
Suite 300-235 15th Street
West Vancouver
A1
BRITISH COLUMBIA, CANADA
V7T2X1
Executive Officer
Director
Martin
Schmieg
Suite 300-235 15th Street
West Vancouver
A1
BRITISH COLUMBIA, CANADA
V7T2X1
Director
Pharmaceuticals
Decline to Disclose
- 06b
false
2021-06-03
false
true
true
true
false
0
ThinkEquity, a division of Fordham Financial Management, Inc.
20996
None
None
17 BATTERY PLACE, SOUTH
NEW YORK
NY
NEW YORK
10004
CA
CALIFORNIA
NV
NEVADA
NJ
NEW JERSEY
NY
NEW YORK
false
27195924
27195924
0
Offering consists of 4,370,343 common shares at a purchase price of USD 5.26; 800,000 pre-funded warrants at a purchase price of USD 5.25 with an exercise price of USD 0.01 per share and 5,170,343 warrants with an exercise price of USD 6.19 per share
false
12
2175680
0
The above amount reflects a cash fee equal to 8% of gross proceeds, including exercise price of the pre-funded warrants. The Placement Agent also received a number of warrants equal to 5% of the Units sold in this offering.
0
true
false
BriaCell Therapeutics Corp.
/s/ William V. Williams
William V. Williams
Chief Executive Officer
2021-06-15